European urology最新文献

Oncological Benefits of Extended Pelvic Lymph Node Dissection: More Fog or Clarity to the Debate?

IF 23.4 1区医学

European urology Pub Date : 2024-12-24 DOI: 10.1016/j.eururo.2024.12.001

Matthew J. Roberts, Philip Cornford, Derya Tilki

引用次数: 0

Re: Michael Baboudjian, Hashim Hashim, Nikita Bhatt, et al. Summary Paper on Underactive Bladder from the European Association of Urology Guidelines on Non-neurogenic Male Lower Urinary Tract Symptoms. Eur Urol 2024;86:213–20

IF 23.4 1区医学

European urology Pub Date : 2024-12-24 DOI: 10.1016/j.eururo.2024.11.028

Aravindh Rathinam, Jonathan Katz, Robert Marcovich, Hemendra N. Shah

引用次数: 0

Pembrolizumab Retreatment in Patients with Advanced or Metastatic Urothelial Carcinoma Who Responded to First-course Pembrolizumab-based Therapy

IF 23.4 1区医学

European urology Pub Date : 2024-12-21 DOI: 10.1016/j.eururo.2024.11.012

Vadim S. Koshkin, Pongwut Danchaivijitr, Woo Kyun Bae, Andrey Semenov, Ozgur Ozyilkan, Yu-Li Su, José A. Arranz Arija, Masao Tsujihata, Martin Bögemann, Mathijs P. Hendriks, Silvia Neciosup Delgado, Eli Rosenbaum, Karla Alejandra Lopez, Abhishek Bavle, Chih-Chin Liu, Kentaro Imai, Andrea Furka

{"title":"Pembrolizumab Retreatment in Patients with Advanced or Metastatic Urothelial Carcinoma Who Responded to First-course Pembrolizumab-based Therapy","authors":"Vadim S. Koshkin, Pongwut Danchaivijitr, Woo Kyun Bae, Andrey Semenov, Ozgur Ozyilkan, Yu-Li Su, José A. Arranz Arija, Masao Tsujihata, Martin Bögemann, Mathijs P. Hendriks, Silvia Neciosup Delgado, Eli Rosenbaum, Karla Alejandra Lopez, Abhishek Bavle, Chih-Chin Liu, Kentaro Imai, Andrea Furka","doi":"10.1016/j.eururo.2024.11.012","DOIUrl":"https://doi.org/10.1016/j.eururo.2024.11.012","url":null,"abstract":"Patients with metastatic solid tumors who previously had stable disease or a response with immunotherapy may derive benefit from immunotherapy retreatment. This post hoc analysis evaluated pembrolizumab retreatment in patients with advanced/metastatic urothelial carcinoma who received pembrolizumab in KEYNOTE-045, KEYNOTE-052, or KEYNOTE-361, and either stopped pembrolizumab after a complete response (CR) or completed pembrolizumab (35 cycles [∼2 yr]) with an objective response or stable disease. Upon disease progression, protocol-specified pembrolizumab retreatment (200 mg intravenously every 3 wk) was administered for ≤17 cycles. Forty-nine patients met the criteria and were included. The median follow-up was 24.4 mo (range, 1.4–53.5). The median time between first-course therapy cessation and pembrolizumab retreatment was 10.7 mo (1.0–36.3). Twenty patients (41%) had an objective response with pembrolizumab retreatment, 65% of whom had a CR to first-course treatment. The median retreatment duration was 8.3 mo (range, 0.0–13.2); the median duration of response was 14.0 mo (2.1+ to 20.5). From retreatment initiation, the median (95% confidence interval) progression-free survival and overall survival were 9.5 mo (5.6–15.0) and 25.7 mo (21.5–27.5), respectively. Treatment-related adverse events occurred in 45% (grade 3–4: 6%; grade 5: 0%). Data suggest that pembrolizumab retreatment is beneficial and tolerable for some patients with advanced/metastatic urothelial carcinoma who previously had a CR or completed 2 yr of pembrolizumab.","PeriodicalId":12223,"journal":{"name":"European urology","volume":"5 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142867319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Increasing Life Expectancy in Patients with Genitourinary Malignancies: Impact of Treatment Burden on Disease Management and Quality of Life

IF 23.4 1区医学

European urology Pub Date : 2024-12-19 DOI: 10.1016/j.eururo.2024.11.026

Marie-Pier St-Laurent, Bernard Bochner, James Catto, Benjamin J. Davies, Christian Daniel Fankhauser, Tullika Garg, Jill Hamilton-Reeves, Viraj Master, Bente T. Jensen, Susanne V. Lauridsen, Elizabeth Wulff-Burchfield, Sarah P. Psutka

{"title":"Increasing Life Expectancy in Patients with Genitourinary Malignancies: Impact of Treatment Burden on Disease Management and Quality of Life","authors":"Marie-Pier St-Laurent, Bernard Bochner, James Catto, Benjamin J. Davies, Christian Daniel Fankhauser, Tullika Garg, Jill Hamilton-Reeves, Viraj Master, Bente T. Jensen, Susanne V. Lauridsen, Elizabeth Wulff-Burchfield, Sarah P. Psutka","doi":"10.1016/j.eururo.2024.11.026","DOIUrl":"https://doi.org/10.1016/j.eururo.2024.11.026","url":null,"abstract":"<h3>Background and objective</h3>Treatment burden refers to the overall impact of medical treatments on a patient’s well-being and daily life. Our objective is to evaluate the impact of treatment burden on quality of life (QoL) in patients with genitourinary (GU) malignancies, highlighting the importance of patient-reported outcomes (PROs) in clinical trials to inform treatment decisions and improve patient care.<h3>Methods</h3>We conducted a narrative review of clinical trials focused on GU malignancy (prostate, bladder, and kidney) between January 2000 and June 2024, analyzing related PROs and findings regarding treatment burden.<h3>Key findings and limitations</h3>Recent landmark clinical trials demonstrate significant improvements in overall survival across GU malignancies with novel therapies. However, the reporting of QoL outcomes in these trials is often inadequate, with many lacking comprehensive data or long-term impact. Current publications are increasingly evaluating treatment burden and its impact on patient well-being as a critical outcome, but most clinical trials to date have failed to assess treatment burden across key domains including financial, time and travel, and medication management.<h3>Conclusions and clinical implications</h3>While advancements in treatment have extended longevity in patients with GU malignancies, the treatment burden associated with the receipt of novel agents and its implications for QoL remain inadequately uncharacterized.","PeriodicalId":12223,"journal":{"name":"European urology","volume":"10 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142857693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Use of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Nodal Staging in Prostate Cancer and Tailoring of Treatment: A Continuing Conundrum

IF 23.4 1区医学

European urology Pub Date : 2024-12-18 DOI: 10.1016/j.eururo.2024.11.025

Johan Stranne, Ann Henry, Daniela E. Oprea-Lager

引用次数: 0

Optimal Treatment Strategies for Hormone-sensitive Metastatic Prostate Cancer: Does Local Radiotherapy Play a Role in High-volume Disease?

IF 23.4 1区医学

European urology Pub Date : 2024-12-17 DOI: 10.1016/j.eururo.2024.12.003

Steven Tisseverasinghe, Marwan Tolba, Fred Saad, Karim Fizazi, Boris Bahoric, Tamim Niazi

引用次数: 0

The Discrepancy Between Patient-reported Outcomes, Adverse Events, and Radiographic Progression-free Survival in MAGNITUDE and Other Recent Trials MAGNITUDE 和其他近期试验中患者报告的结果、不良事件和无放射进展生存期之间的差异